Sensyne Health PLC (AIM:SENS, FRA:DSH) launched an AI-enabled global data analytics platform for the healthcare and life sciences sectors.
Called SENSIGHT, the platform uses data derived from around 10mln anonymised and de-identified patients accumulated from research partnerships with NHS Trusts and US health systems.
It is the first platform of its type to provide industrial-scale access for research, said the AIM-listed group, with the plan to add new tools and grow the database to 100mln patients by the end of 2024.
Available by subscription at a cost of £25,000 per person per year for commercial customers, the system will be free to NHS Trust partners.
Lord Drayson chief executive, added: "Sensyne Health was founded to bring the power of clinical AI and health data analytics to improve patient outcomes, reduce healthcare costs and accelerate the discovery and development of new medicines.
"For several years we have worked within an ethical, transparent, and fair framework that ensures patient data privacy and security and shares the commercial return from our work with healthcare providers such as the NHS and health systems in the US.
"SENSIGHT now enables us to exponentially scale that vision and creates a new channel for our other products and services.”